Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
5 hedge funds and large institutions have $6.98M invested in Kite Pharma, Inc. in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.63% more ownership
Funds ownership: 0% → 0.63% (+0.63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Frontier Capital Management
Boston,
Massachusetts
|
+$2.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.88M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.17M |
| 4 |
Emerald Advisers
Leola,
Pennsylvania
|
+$1.11M |
| 5 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$529K |
Top Sellers
KITE Hedge Fund Activity: Q2 2014 in Review
5 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q2 2014, worth a combined $6.98M.
Buyers outnumbered sellers: 5 funds opened new KITE positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frontier Capital Management, opening a new position worth an estimated $2.5M.
- 5 institutional investors held Kite Pharma, Inc. (KITE) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $6.98M of Kite Pharma, Inc. stock for Q2 2014.
- 5 funds opened new Kite Pharma, Inc. positions in Q2 2014 and 0 closed out, a net change of +5 holders.
- The largest Kite Pharma, Inc. buyer in Q2 2014 was Frontier Capital Management, an estimated $2.5M added.
Based on aggregated 13F filings for Q2 2014.